3 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 3 |
| Phase 2 | 3 | Unknown 3 |
Follow ASIS Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASIS for Enbrel in Plaque Psoriasis Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24 - Plaque Psoriasis. | Phase 1 / Phase 2 | Unknown | ASIS Corporation | 60 | 2016-01-01 | 2015-06-24 |
| ASIS for Botox in Chronic Migraine Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12 - Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer. | Phase 1 / Phase 2 | Unknown | ASIS Corporation | 60 | 2016-01-01 | 2015-06-24 |
| ASIS for GAMMAGARD in Primary Immunodeficiency Gadolinium For abdomen, Gadolinium For lower back, Efficacy of Gammagard subcutaneously at Week 12 - Primary Immunodeficiency | Phase 1 / Phase 2 | Unknown | ASIS Corporation | 60 | 2016-01-01 | 2015-06-24 |
Primary Immunodeficiency Diseases (1)
Gadolinium (3) · Gadolinium DTPA (3) · Botulinum Toxins, Type A (1) · Etanercept (1) · Immunoglobulins, Intravenous (1)
United States (3)
Li Nguyen, MD (3) · Thanh Phung, MD (2) · Hanh Nguyen, MD (1) · Thanh Phung,, MD (1)